Launched in 2020 to more quickly bring to market an effective medicine for amyotrophic lateral sclerosis, the HEALEY Platform ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our ...

Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales ...

Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

Plus, learn about what to expect in initial interviews and how to time your post-Ph.D. job search for maximum success.

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...